Cascadian Therapeutics (ONTY) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 12, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Oncothyreon Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	69,314,108
Amendment Flag	'false	'
Entity Central Index Key	'0001412067	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Accelerated Filer	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (current period unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current:	'	'
Cash and cash equivalents	$12,774	$22,266
Short-term investments	48,582	58,988
Accounts and other receivables	1,687	323
Prepaid and other current assets	1,048	840
Total current assets	64,091	82,417
Long-term investments	10,560	2,502
Property and equipment, net	1,819	1,887
Goodwill	2,117	2,117
Other assets	644	512
Total assets	79,231	89,435
Current:	'	'
Accounts payable	677	1,133
Accrued and other liabilities	1,920	852
Accrued compensation and related liabilities	1,065	1,042
Current portion of restricted share unit liability	244	44
Current portion of warrant liability	215	'
Total current liabilities	4,121	3,071
Deferred rent	463	533
Restricted share unit liability	201	227
Warrant liability	1,910	3,251
Class UA preferred stock, 12,500 shares authorized, 12,500 shares issued and outstanding	30	30
	6,725	7,112
Commitments and contingencies	'	'
Stockholders’ equity:	'	'
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.0001 par value; 100,000,000 shares authorized, 68,060,844 and 57,216,237 shares issued and outstanding	353,854	353,853
Additional paid-in capital	149,409	126,832
Accumulated deficit	-425,722	-393,326
Accumulated other comprehensive loss	-5,035	-5,036
Total stockholders’ equity	72,506	82,323
Total liabilities and stockholders’ equity	$79,231	$89,435

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (current period unaudited) (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Class UA preferred stock, shares authorized, issued and outstanding	12,500	12,500
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	68,060,844	57,216,237
Common stock, shares outstanding	68,060,844	57,216,237

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Operating expenses	'	'	'	'
Research and development	$5,517	$5,783	$27,374	$16,348
General and administrative	2,085	1,902	6,266	5,181
Total operating expenses	7,602	7,685	33,640	21,529
Loss from operations	-7,602	-7,685	-33,640	-21,529
Other income (expenses)	'	'	'	'
Investment and other income (expenses), net	66	32	118	-167
Interest expense	'	'	'	-309
Change in fair value of warrant liability	-174	-972	1,126	14,336
Total other income (expenses), net	-108	-940	1,244	13,860
Net loss	($7,710)	($8,625)	($32,396)	($7,669)
Net loss per share—basic (in Dollars per share)	($0.12)	($0.15)	($0.54)	($0.15)
Net loss per share—diluted (Note 6) (in Dollars per share)	($0.12)	($0.15)	($0.54)	($0.41)
Shares used to compute basic net loss per share (in Shares)	63,886,874	57,186,749	59,962,328	52,564,914
Shares used to compute diluted net loss per share (in Shares)	63,886,874	57,186,749	59,962,328	53,899,276

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net loss	($7,710)	($8,625)	($32,396)	($7,669)
Unrealized gain (loss) during the period, net	22	38	1	8
Reclassification adjustment	'	'	'	1
Other comprehensive income	22	38	1	9
Comprehensive loss	($7,688)	($8,587)	($32,395)	($7,660)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities	'	'
Net loss	($32,396)	($7,669)
Depreciation and amortization	367	396
Amortization of discount and deferred financing costs on notes payable	'	78
Amortization of premiums and accretion of discounts on securities	473	587
Share-based compensation expense	1,628	992
Change in fair value of warrant liability	-1,126	-14,336
Cash settled on conversion of restricted share units	-11	-39
Other	-45	264
Accounts and other receivable	84	-111
Prepaid expenses and other current assets	-208	-525
Other long term assets	-132	-79
Accounts payable	-456	1,475
Accrued and other liabilities	1,068	-280
Accrued compensation and related liabilities	23	77
Deferred rent	-70	-63
Net cash used in operating activities	-30,801	-19,233
Cash flows from investing activities	'	'
Purchases of investments	-50,190	-72,037
Redemption of investments	52,066	45,698
Purchases of property and equipment, net	-253	-686
Net cash provided by (used in) investing activities	1,623	-27,025
Cash flows from financing activities	'	'
Proceeds from issuance of common stock, net of issuance cost	19,686	50,377
Principal payments on notes payable	'	-909
Repayment on notes payable	'	-4,135
Net cash provided by financing activities	19,686	45,333
Decrease in cash and cash equivalents	-9,492	-925
Cash and cash equivalents, beginning of period	22,266	11,609
Cash and cash equivalents, end of period	$12,774	$10,684

Note_1_Description_of_Business

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	1.       DESCRIPTION OF BUSINESS
	Oncothyreon Inc. (the Company), is a clinical-stage biopharmaceutical company incorporated in the State of Delaware on September 7, 2007. The Company is focused primarily on the development of therapeutic products for the treatment of cancer. The Company’s goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The Company’s operations are not subject to any seasonality or cyclicality factors.

Note_2_Basis_of_Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	2.       BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial statements. The accounting principles and methods of computation adopted in these condensed consolidated financial statements are the same as those of the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities Exchange Commission (the SEC), on March 14, 2013.
	Omitted from these statements are certain information and note disclosures normally included in the audited consolidated financial statements prepared in accordance with U.S. GAAP. The Company believes all adjustments necessary for a fair statement of the results for the periods presented have been made, and such adjustments consist only of those considered normal and recurring in nature. The financial results for the three and nine months ended September 30, 2013 are not necessarily indicative of financial results for the full year. The condensed consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date. The unaudited condensed consolidated financial statements and notes presented should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC on March 14, 2013.
	Reclassifications
	The Company reclassified amortization of premiums and accretion of discounts on securities out of investing activities into operating activities. The prior years’ amortization of premiums and accretion of discounts were reclassified for consistency with current period presentation. These reclassifications had no effect on reported operating expenses, loss from operations, or net loss.
	Accumulated Other Comprehensive Income (Loss)
	Comprehensive income or loss is comprised of net income or loss and other comprehensive income or loss. Other comprehensive income or loss includes unrealized gains and losses on the Company’s available-for-sale investments. In addition to unrealized gains and losses on investments, accumulated other comprehensive income or loss consists of foreign currency translation adjustments which arose from the conversion of the Canadian dollar functional currency consolidated financial statements to the U.S. dollar reporting currency consolidated financial statements prior to January 1, 2008. Should the Company liquidate or substantially liquidate its investments in its foreign subsidiaries, the Company would be required to recognize the related cumulative translation adjustments pertaining to the liquidated or substantially liquidated subsidiaries, as a charge to earnings in the Company’s condensed consolidated statement of operations and comprehensive loss.
	There were no reclassifications out of accumulated other comprehensive loss during the three and nine months ended September 30, 2013. The table below shows the changes in accumulated balances of each component of accumulated other comprehensive loss for the three and nine months ended September 30, 2013:
		Three months ended September 30, 2013
		Net unrealized		Foreign			Accumulated
		gains/(losses) on		Currency			Other
		Available-for-sale		Translation			Comprehensive
		Securities		Adjustment			Loss
		(In thousands)
	Balance at June 30, 2013	$	9	$	(5,066	)	$	(5,057	)
	Current period other comprehensive income		22		—			22
	Balance at September 30, 2013	$	31	$	(5,066	)	$	(5,035	)
		Nine months ended September 30, 2013
		Net unrealized		Foreign			Accumulated
		gains/(losses) on		Currency			Other
		Available-for-sale		Translation			Comprehensive
		Securities		Adjustment			Loss
		(In thousands)
	Balance at December 31, 2012	$	30	$	(5,066	)	$	(5,036	)
	Current period other comprehensive income		1		—			1
	Balance at September 30, 2013	$	31	$	(5,066	)	$	(5,035	)

Note_3_Recent_Accounting_Prono

Note 3 - Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2013
Table Text Block [Abstract]	'
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	'
	3.       RECENT ACCOUNTING PRONOUNCEMENTS
	In July 2013, the Financial Accounting Standards Board (FASB) issued guidance on presentation of an unrecognized tax benefit in financial statements when a net operating loss (NOL) carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for an NOL carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when (1) the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and (2) the entity intends to use the deferred tax asset for that purpose. The guidance does not require new recurring disclosures. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013 for public entities. Early adoption and retrospective application are permitted. The adoption of this standard is not expected to have impact on the presentation of the Company’s unrecognized tax benefits or on the consolidated financial position or results of operations.
	In February 2013, FASB issued new guidance on reporting of amounts reclassified out of accumulated other comprehensive income. This guidance requires an entity to disclose the amount reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present either on the face of the Consolidated Statements of Operations or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about these amounts. The guidance does not change the current requirements for reporting net income or other comprehensive income in financial statements. The guidance is effective for all reporting periods (interim and annual) beginning after December 15, 2012. The adoption of this guidance on January 1, 2013 had no impact on the Company’s consolidated financial position or results of operations.

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	4.       FAIR VALUE MEASUREMENTS
	The Company measures certain financial assets and liabilities at fair value in accordance with a hierarchy which requires an entity to maximize the use of observable inputs which reflect market data obtained from independent sources and minimize the use of unobservable inputs which reflect the Company’s market assumptions when measuring fair value. There are three levels of inputs that may be used to measure fair value:
		•	Level 1—quoted prices in active markets for identical assets or liabilities;
		•	Level 2—observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
		•	Level 3—unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial assets and liabilities measured at fair value consisted of the following as of September 30, 2013 and December 31, 2012:
			30-Sep-13								31-Dec-12
			Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
			(In thousands)
	Financial assets:
	Money market funds		$	10,636	$	—	$	—	$	10,636	$	19,859	$	—	$	—	$	19,859
	Debt securities of U.S. government agencies			—		45,602		—		45,602		—		52,444		—		52,444
	Corporate bonds			—		13,540		—		13,540		—		9,046		—		9,046
			$	10,636	$	59,142	$	—	$	69,778	$	19,859	$	61,490	$	—	$	81,349
	Financial liabilities:
	Restricted share units		$	445	$	—	$	—	$	445	$	271	$	—	$	—	$	271
	Warrants		$	—	$	—	$	2,125	$	2,125	$	—	$	—	$	3,251	$	3,251
	If quoted market prices in active markets for identical assets are not available to determine fair value, then the Company uses quoted prices of similar instruments and other significant inputs derived from observable market data obtained from third-party data providers. These investments are included in Level 2 and consist of debt securities of U.S government agencies and corporate bonds. There were no transfers between Levels 1 and 2 during the three and nine month periods ending September 30, 2013 and 2012. The Company classifies its warrant liability within Level 3 because the warrant liability is valued using valuation models with significant unobservable inputs. The estimated fair value of warrants accounted for as liabilities was determined on the issuance date and are subsequently remeasured to fair value at each reporting date. The change in fair value of the warrants is recorded in the statement of operations as other income or other expense estimated by using the Black-Scholes option-pricing model. A discussion of the valuation techniques and inputs to determine fair value of these instruments is included in Note 8.

Note_5_Financial_Instruments

Note 5 - Financial Instruments	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Financial Instruments Disclosure [Text Block]	'
	5.       FINANCIAL INSTRUMENTS
	Financial instruments consist of cash and cash equivalents, investments and accounts and other receivables that will result in future cash receipts, as well as accounts payable, accrued and other liabilities, restricted share unit liabilities, warrant liabilities and Class UA preferred stock that may require future cash outlays.
	Investments
	Investments are classified as available-for-sale securities and are carried at fair value with unrealized temporary holding gains and losses, where applicable, excluded from net income or loss and reported in other comprehensive income or loss and also as a net amount in accumulated other comprehensive income or loss until realized. Available-for-sale securities are written down to fair value through income whenever it is necessary to reflect an other-than-temporary impairment. The Company determined that the unrealized losses on its marketable securities as of September 30, 2013 were temporary in nature, and the Company currently does not intend to sell these securities before recovery of their amortized cost basis. All short-term investments are limited to a final maturity of less than one year from the reporting date. The Company’s long-term investments are investments with maturities exceeding 12 months but less than five years from the reporting date. The Company is exposed to credit risk on its cash equivalents, short-term investments and long-term investments in the event of non-performance by counterparties, but does not anticipate such non-performance and mitigates exposure to concentration of credit risk through the nature of its portfolio holdings. If a security falls out of compliance with the Company’s investment policy, it may be necessary to sell the security before its maturity date in order to bring the investment portfolio back into compliance. The fair value of available-for-sale securities is based on prices obtained from a third-party pricing service. The Company utilizes third-party pricing services for all of its marketable debt security valuations.  The Company reviews the pricing methodology used by the third-party pricing services including the manner employed to collect market information.  On a periodic basis, the Company also performs review and validation procedures on the pricing information received from the third-party pricing services. These procedures help ensure that the fair value information used by the Company is determined in accordance with applicable accounting guidance. The amortized cost, unrealized gain or losses and fair value of the Company’s cash, cash equivalents and investments for the periods presented are summarized below:
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(In thousands)
	As of September 30, 2013
	Cash	$	2,138	$	—	$	—		$	2,138
	Money market funds		10,636		—		—			10,636
	Debt securities of U.S. government agencies		45,581		21		—			45,602
	Corporate bonds		13,530		10		—			13,540
	Total	$	71,885	$	31	$	—		$	71,916
	As of December 31, 2012
	Cash	$	2,407	$	—	$	—		$	2,407
	Money market funds		19,859		—		—			19,859
	Debt securities of U.S. government agencies		52,415		29		—			52,444
	Corporate bonds		9,045		3		(2	)		9,046
	Total	$	83,726	$	32	$	(2	)	$	83,756
	The following table summarizes the Company’s available-for-sale securities by contractual maturity:
		As of September 30, 2013				As of December 31, 2012
		Amortized		Fair		Amortized			Fair
		Cost		Value		Cost			Value
		(In thousands)
	Less than one year	$	59,196	$	59,218	$	78,819		$	78,847
	Greater than one year but less than five years		10,551		10,560		2,500			2,502
	Total	$	69,747	$	69,778	$	81,319		$	81,349
	Accounts and Other Receivables, Accounts Payable and Accrued and Other Liabilities
	The carrying amounts of accounts and other receivables, accounts payable and accrued and other liabilities approximate their fair values due to the short-term nature of these financial instruments.
	Class UA Preferred Stock
	The fair value of class UA preferred stock is assumed to be equal to its carrying value as the amounts that will be paid and the timing of the payments cannot be determined with any certainty.
	Limitations
	Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment; therefore, they cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

Note_6_Net_Loss_Per_Share

Note 6 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	6.       NET LOSS PER SHARE
	Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share is calculated by adjusting the numerator and denominator of the basic net loss per share calculation for the effects of all potentially dilutive common shares. Potential dilutive shares of the Company’s common stock include stock options, restricted share units, warrants and shares granted under the 2010 Employee Stock Purchase Plan (ESPP). The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to loss per share for the period, adjustments to net loss used in the calculation are required to remove the change in fair value of the warrants for the period. Furthermore, adjustments to the denominator are required to reflect the addition of the related dilutive shares.
	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share for the three and nine months ended September 30, 2013 and September 30, 2012:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
		(in thousands, except share and per share amounts)
	Numerator
	Net loss used to compute net loss per share
	Basic	$	(7,710	)	$	(8,625	)	$	(32,396	)	$	(7,669	)
	Adjustments for change in fair value of warrant liability		—			—			—			(14,336	)
	Diluted	$	(7,710	)	$	(8,625	)	$	(32,396	)	$	(22,005	)
	Denominator
	Weighted average shares outstanding used to compute net loss per share:
	Basic		63,886,874			57,186,749			59,962,328			52,564,914
	Dilutive effect of warrants		—			—			—			1,334,362
	Diluted		63,886,874			57,186,749			59,962,328			53,899,276
	Net loss per share—basic	$	(0.12	)	$	(0.15	)	$	(0.54	)	$	(0.15	)
	Net loss per share—diluted	$	(0.12	)	$	(0.15	)	$	(0.54	)	$	(0.41	)
	The following table presents the number of shares that were excluded from the number of shares used to calculate diluted net loss per share:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Director and employee stock options		2,909,699			2,482,862			2,909,699			2,482,862
	Warrants		10,922,090			5,922,089			10,922,090			48,701
	Non-employee director restricted share units		215,829			140,968			215,829			140,968
	Employee stock purchase plan		23,374			19,223			23,374			19,223

Note_7_Equity_Based_Transactio

Note 7 - Equity Based Transactions	9 Months Ended
	Sep. 30, 2013
Stockholders Equity Transactions Note Disclosure [Abstract]	'
Stockholders Equity Transactions Note Disclosure [Text Block]	'
	7.     EQUITY BASED TRANSACTIONS
	Equity Financing
	On June 4, 2013, the Company closed a registered direct offering of 5,000,000 units, with each unit consisting of one share of the Company’s common stock and a warrant to purchase one share of the Company’s common stock, at $2.00 per unit for gross proceeds of $10 million. The warrants are exercisable at an exercise price of $5.00 per share any time on or after December 5, 2013 and expire December 5, 2018. The shares and warrants were sold to Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. in a registered direct offering conducted without an underwriter or placement agent. The net proceeds from the offering, after deducting estimated offering expenses, were approximately $9.9 million.
	On April 3, 2012, the Company closed an underwritten public offering of 13,512,500 shares of its common stock at a price to the public of $4.00 per share for gross proceeds of approximately $54.1 million. The net proceeds from the sale of the shares, after deducting the underwriters’ discounts and other offering expenses payable by the Company, were approximately $50.3 million.
	“At-the-Market” Program
	On February 3, 2012, the Company entered into a Sales Agreement with Cowen and Company, LLC (the Sales Agreement) to sell shares of the Company’s common stock, having aggregate gross sales proceeds up to $50,000,000, from time to time, through an “at the market” equity offering program under which Cowen and Company, LLC (Cowen) will act as sales agent. Under the Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that Cowen will be entitled to compensation for its services that will not exceed, but may be lower than, 3.0% of the gross sales price per share of all shares sold through Cowen under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement, and may at any time suspend solicitation and offers under the Sales Agreement. On July 1, 2013, the Company commenced selling its common stock through the “at the market” equity offering program under the Sales Agreement. During the three months ended September 30, 2013, the Company sold an aggregate of 5,791,697 shares for gross proceeds of $11.5 million. The net proceeds from the sale of the shares, after deducting commission of approximately $0.3 million, were approximately $11.2 million. That amount includes $1.4 million of net proceeds that were pending settlement as of September 30, 2013, which are recorded in this Form 10-Q in accounts and other receivables. The pending settlement amount was received in October 2013. As of September 30, 2013, approximately $38.5 million of the Company’s common stock remained available for sale under the “at the market” equity offering program.

Note_8_Warrants

Note 8 - Warrants	9 Months Ended
	Sep. 30, 2013
Warrants and Rights Note Disclosure [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	8. WARRANTS
	Warrants consist of liability-classified warrants and equity-classified warrants. As of September 30, 2013, warrants to purchase a total of 10,922,090 shares of the Company’s common stock were outstanding. No warrants expired or were exercised in each of the three and nine months ended September 30, 2013 and September 30, 2012.
	Equity-Classified Warrants
	Equity-classified warrants consist of warrants issued in connection with the Company’s registered direct offering to Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. (collectively, BVF) and warrants issued in connection with a term loan with General Electric Capital Corporation (GECC). In June 2013, the Company issued warrants to purchase 5,000,000 shares of common stock at an exercise price of $5.00 per share in connection with a registered direct offering to BVF. The warrants expire on December 5, 2018. In February 2011, the Company issued warrants to purchase 48,701 shares of common stock at an exercise price of $3.08 per share in connection with a loan and security agreement entered into with GECC. The warrants expire on February 8, 2018. As of September 30, 2013, warrants to purchase 5,048,701 shares of common stock were outstanding and classified as equity.
	Liability-Classified Warrants
	Liability-classified warrants consist of warrants issued in conjunction with equity financings in May 2009 and September 2010. The warrants issued in May 2009 and September 2010 have been classified as liabilities, as opposed to equity, due to potential cash settlement upon the occurrence of certain transactions specified in the warrant agreement. As of September 30, 2013, warrants to purchase 2,691,242 and 3,182,147 shares of the Company’s common stock, from the May 2009 and September 2010 financings respectively, totaling 5,873,389 shares, were outstanding and classified as a liability.
	The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. The change in the estimated fair value of such warrants is recorded in the condensed consolidated statement of operations as other income (expenses). The fair value of the warrants is estimated using the Black-Scholes option-pricing model with the following inputs for the warrants:
		As of September 30, 2013
		May-09			Sep-10
		Warrants			Warrants
	Exercise price	$	3.74		$	4.24
	Market value of stock at end of period	$	2.06		$	2.06
	Expected dividend rate		0	%		0.00%
	Expected volatility		61.5	%		88.5	%
	Risk-free interest rate		0.1	%		0.3	%
	Expected life (in years)		0.65			2.03
		As of December 31, 2012
		May-09			Sep-10
		Warrants			Warrants
	Exercise price	$	3.74		$	4.24
	Market value of stock at end of period	$	1.92		$	1.92
	Expected dividend rate		0	%		0	%
	Expected volatility		99.2	%		81.1	%
	Risk-free interest rate		0.2	%		0.3	%
	Expected life (in years)		1.4			2.78
	The fair value of the warrant liability and the changes in its fair value during the three and nine months ended September 30, 2013 and September 30, 2012 were as follows:
		Three months ended September 30,
		2013			2012
		(In thousands)
	Balance at beginning of period	$	1,951		$	13,463
	Change in fair value of warrant liability included in:
	Other expense (income)		174			972
	Balance at the end of period	$	2,125		$	14,435
		Nine months ended September 30,
		2013			2012
		(In thousands)
	Balance at beginning of period	$	3,251		$	28,771
	Change in fair value of warrant liability included in:
	Other expense (income)		(1,126	)		(14,336	)
	Balance at the end of period	$	2,125		$	14,435
	Expected volatility is an unobservable input that is inter-related with the market value or price of the Company’s stock, since the calculation of volatility is based on the Company’s historical closing prices. If volatility were to increase or decrease by 10%, the value of the warrant liability would increase or decrease respectively, by approximately $0.4 million.

Note_9_Sharebased_Compensation

Note 9 - Share-based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	9.       SHARE-BASED COMPENSATION
	Share Option Plan
	The Company sponsors an option plan (the Share Option Plan) under which a maximum fixed reloading percentage of 10% of the issued and outstanding common stock of the Company may be granted to employees, directors and service providers. Options granted under the Share Option Plan prior to January 2010 began vesting after one year from the date of grant, are exercisable in equal amounts over four years on the anniversary date of the grant, and expire eight years following the date of grant. Options granted under the Share Option Plan after January 2010 vest 25% on the first anniversary of the hiring date, with the balance vesting in monthly increments for 36 months following the first anniversary of hiring, and expire eight years following the date of grant. As of September 30, 2013, the number of shares of common stock reserved for issuance under the Share Option Plan was 6,806,084. As of September 30, 2013, 2,794,003 shares of common stock remained available for future grant under the Share Option Plan.
	During the three months ended September 30, 2013 and September 30, 2012, the Company granted 10,000 and 75,000 stock options, respectively, and recorded stock compensation expense of $0.4 million and $0.3 million, respectively. During the nine months ended September 30, 2013 and September 30, 2012, the Company granted 10,000 and 100,500 stock options, respectively, and recorded stock compensation expense of $1.3 million and $1.0 million, respectively. Stock options granted during the nine months ended September 30, 2012 were higher due to the addition of an increased number of new employees during the period. No stock options were exercised during each of the three and nine months ended September 30, 2013 and September 30, 2012.
	The Company uses the Black-Scholes option pricing model to value the options at each grant date, using the following weighted average assumptions:
		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Weighted average grant-date fair value for stock options granted	$	1.27		$	3.62		$	1.27		$	3.63
	Expected dividend rate		0	%		0	%		0	%		0	%
	Expected volatility		89.64	%		84.78	%		89.64	%		84.62	%
	Risk-free interest rate		1.8	%		0.86	%		1.8	%		0.9	%
	Expected life of options in years		6			6			6			6
	The expected term represents the period that the Company’s stock options are expected to be outstanding and was determined based on the simplified method, which calculates the expected life as the average of the vesting term and the contractual term of the option. The Company’s historical stock option exercise data was impacted by a restructuring of its business in 2008. Because the Company does not have sufficient historical stock option exercise data to accurately estimate the expected term used for its valuation of stock options, the Company continues to use the simplified method to calculate the expected term of new stock option grants. As the Company accumulates more data and history related to the exercises of stock option awards, the Company will reassess its use of the simplified method to determine the expected term.
	Employee Stock Purchase Plan
	The Company adopted an Employee Stock Purchase Plan (ESPP) on June 3, 2010, pursuant to which a total of 900,000 shares of common stock were reserved for sale to employees of the Company. The ESPP is administered by the compensation committee of the board of directors and is open to all eligible employees of the Company. Under the terms of the ESPP, eligible employees may purchase shares of the Company’s common stock at six month intervals during 18-month offering periods through periodic payroll deductions, which may not exceed 15% of any employee’s compensation and may not exceed a value of $25,000 in any calendar year, at a price not less than the lesser of an amount equal to 85% of the fair market value of the Company’s common stock at the beginning of the offering period or an amount equal to 85% of the fair market value of the Company’s common stock on each purchase date. The maximum aggregate number of shares that may be purchased by each eligible employee during each offering period is 15,000 shares of the Company’s common stock. For the three and nine months ended September 30, 2013, expense related to this plan was $44,273 and $107,847, respectively. For the three and nine months ended September 30, 2012, expense related to this plan was $54,928 and $134,030, respectively. Under the ESPP, the Company did not issue any shares to employees during each of the three months periods ended September 30, 2013 and September 30, 2012. The Company issued 35,895 shares and 28,591 shares to employees during the nine months ended September 30, 2013 and September 30, 2012, respectively. There are 716,278 shares reserved for future issuances under the ESPP as of September 30, 2013.
	Restricted Share Unit Plan
	The Company also sponsors a restricted share unit plan (RSU Plan) for non-employee directors that was established in 2005. The RSU Plan provides for grants to be made from time to time by the board of directors or a committee thereof. Each unit granted will be made in accordance with the RSU Plan and terms specific to that grant and will be converted into one share of common stock less the cash payment provisions described below at the end of the grant period (not to exceed five years) without any further consideration payable to the Company in respect thereof. The current maximum number of common shares of the Company reserved for issuance pursuant to the RSU Plan is 466,666. As of September 30, 2013, 79,022 shares of common stock remain available for future grant under the RSU Plan. During the three months ended September 30, 2013, the Company granted 17,341 restricted share units (RSUs) with a fair value of $30,000 to its new board member. The Company did not grant any RSUs during the three months ended September 30, 2012. The Company granted 97,551 and 40,870 RSUs, with a fair value of $180,000 and $150,000 during nine months ended September 30, 2013 and September 30, 2012, respectively. No shares were issued upon conversion of RSUs for the three months ended September 30, 2013 and September 30, 2012. During the nine months ended September 30, 2013 and September 30, 2012, 22,690 and 43,397 shares were issued upon conversion of RSUs, respectively. The fair value of each RSU has been determined to be the closing trading price of the Company’s common shares on the date of grant as quoted in NASDAQ Global Market.
	Approximately 25% of each RSU represents a contingent right to receive cash upon vesting, and the Company is required to deliver an amount in cash equal to the fair market value of the shares on the vesting date to facilitate the satisfaction of the non-employee directors’ U.S. federal income tax obligation with respect to the vested RSUs. The outstanding RSU awards are required to be remeasured at each reporting date until settlement of the award, and changes in valuation are recorded as compensation expense for the period. To the extent that the liability recorded in the balance sheet is less than the original award value, the difference is recognized in equity. The fair value of the outstanding RSUs on the reporting date is determined to be the closing trading price of the Company’s common shares on that date.
	The remeasurement of the outstanding RSUs resulted in an additional $0.1 million and $0.2 million in share-based compensation expense recorded in general and administrative expenses in the condensed consolidated statement of operations for the three and nine months ended September 30, 2013, respectively. The remeasurement of the outstanding RSUs resulted in an additional $0.1 million and a reduction of $0.2 million in share-based compensation expense recorded in general and administrative expenses in the condensed consolidated statement of operations for the three and nine months ended September 30, 2012, respectively.

Note_10_Contingencies_Commitme

Note 10 - Contingencies, Commitments, and Guarantees	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Commitments Contingencies and Guarantees [Text Block]	'
	10.      CONTINGENCIES, COMMITMENTS, AND GUARANTEES
	Litigation Contingency
	On April 30, 2013, a putative shareholder derivative action was filed in the United States District Court for the Western District of Washington, purportedly on behalf of Oncothyreon and naming certain executive officers and the members of our board of directors as defendants.  The complaint asserted claims for breaches of fiduciary duty, unjust enrichment, abuse of control, and mismanagement based on allegedly false statements made by us in public filings and press releases in 2011 and 2012.  The lawsuit sought unspecified damages allegedly sustained by Oncothyreon, which was named in the suit as a nominal defendant, as well as certain corporate reforms, disgorgement, and attorneys’ fees and litigation expenses. On June 24, 2013, the plaintiff in the lawsuit filed an amended complaint asserting the same claims and seeking the same relief.  On July 18, 2013, we filed a motion to dismiss the amended complaint on the basis that the plaintiff lacks standing to pursue derivative claims on behalf of the company. On September 16, 2013, the court entered an order granting our motion and dismissing the lawsuit with prejudice, which means that the plaintiff was not permitted to further amend his complaint to bolster his claims. The period to appeal the dismissal order has now expired, with no appeal being filed, so the lawsuit is concluded.
	Royalties
	In connection with the issuance of the Class UA preferred stock, the Company has agreed to pay to the holders a royalty in the amount of 3% of the net proceeds of sale of any products sold by the Company employing technology acquired in exchange for the shares. None of the Company’s product candidates currently under development employ the technology acquired.
	Pursuant to various license agreements, the Company is obligated to make payments based both on the achievement of certain milestones and a percentage of revenues derived from the licensed technology and royalties on net sales.
	Guarantees
	The Company is contingently liable under a mutual undertaking of indemnification with Merck KGaA of Darmstadt, Germany (Merck KGaA) for any withholding tax liability that may arise from payments under the Company’s agreements with them.
	In the normal course of operations, the Company indemnifies counterparties in transactions such as purchase and sale contracts for assets or shares, service agreements, director/officer contracts and leasing transactions. These indemnification agreements may require the Company to compensate the counterparties for costs incurred as a result of various events, including environmental liabilities, changes in (or in the interpretation of) laws and regulations, or as a result of litigation claims or statutory sanctions that may be suffered by the counterparties as a consequence of the transaction. The terms of these indemnification agreements vary based upon the contract, the nature of which prevents the Company from making a reasonable estimate of the maximum potential amount that could be required to pay to counterparties. Historically, the Company has not made any significant payments under such indemnification agreements and no amounts have been accrued in the accompanying condensed consolidated financial statements with respect to these indemnification guarantees.

Note_11_Collaborative_and_Lice

Note 11 - Collaborative and License Agreements	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborative Arrangement Disclosure [Text Block]	'
	11.      COLLABORATIVE AND LICENSE AGREEMENTS
	Merck KGaA
	The Company has granted an exclusive, worldwide license to Merck KGaA for the development, manufacture and commercialization of tecemotide (formerly known as L-BLP25 or Stimuvax). The Company has no continuing involvement in the ongoing development, manufacturing or commercialization of tecemotide. Under the 2008 license agreement, the Company may receive milestone payments of up to $90 million upon the occurrence of certain specified events. These contingent payments would be recognized as revenue upon the occurrence of such events. The Company is also entitled to receive royalties based on net sales of tecemotide ranging from a percentage in the mid-teens to high single digits, depending on the territory in which the net sales occur. The Company has (1) agreed not to develop any product, other than ONT-10, that is competitive with tecemotide and (2) granted to Merck KGaA a right of first negotiation in connection with any contemplated collaboration or license agreement with respect to the development or commercialization of ONT-10. No amounts were recognized in connection with this agreement during the three and nine months ended September 30, 2013 and September 30, 2012.
	Array BioPharma Inc.
	On May 30, 2013, the Company entered into a collaborative agreement with Array BioPharma Inc. (Array). Under the agreement, Array and the Company will collaborate to develop and commercialize, an orally active, reversible and selective small-molecule HER2 inhibitor which the Company refers to as ONT-380. HER2, also known as ErbB2, is a receptor tyrosine kinase that is over-expressed in breast cancer and other cancers such as gastric and ovarian cancer. Array previously completed a Phase 1 clinical trial of ONT-380 in patients with heavily pre-treated metastatic breast cancer which demonstrated that the compound was well tolerated and had anti-tumor activity.
	The Company paid Array an upfront fee of $10 million, which was recorded as part of research and development expense upon initiation of the collaboration. Under the agreement, the Company will fund and conduct the clinical development of ONT-380 through a defined set of combination proof-of-concept trials in patients with metastatic breast cancer, including patients with brain metastases.
	The Company and Array intend to jointly conduct Phase 3 development supported by the proof-of-concept studies, with each party retaining the right to opt out of further development and commercialization in exchange for a significant royalty. Array is responsible for worldwide commercialization of the product. The Company has a co-promotion right in the U.S., and the two companies will share the cost of U.S. commercialization, including any profit, equally. Outside of the U.S., the Company will receive a double-digit royalty on net sales intended to approximate a fifty percent profit share, and the two companies will share equally the proceeds from any sublicense of marketing rights.

Note_12_Income_Tax

Note 12 - Income Tax	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	12.      INCOME TAX
	Due to actual and projected losses for the years ended December 31, 2013 and 2012, respectively, and the Company’s history of losses, the Company has not recorded an income tax provision for the three and nine months ended September 30, 2013 and September 30, 2012. The Company’s net deferred tax assets and deferred tax liabilities were recorded in other assets and accrued and other liabilities, respectively on the Condensed Consolidated Balance Sheets.

Note_13_Subsequent_Events

Note 13 - Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	13.      SUBSEQUENT EVENTS
	None

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial statements. The accounting principles and methods of computation adopted in these condensed consolidated financial statements are the same as those of the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities Exchange Commission (the SEC), on March 14, 2013.
	Omitted from these statements are certain information and note disclosures normally included in the audited consolidated financial statements prepared in accordance with U.S. GAAP. The Company believes all adjustments necessary for a fair statement of the results for the periods presented have been made, and such adjustments consist only of those considered normal and recurring in nature. The financial results for the three and nine months ended September 30, 2013 are not necessarily indicative of financial results for the full year. The condensed consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date. The unaudited condensed consolidated financial statements and notes presented should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC on March 14, 2013.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications
	The Company reclassified amortization of premiums and accretion of discounts on securities out of investing activities into operating activities. The prior years’ amortization of premiums and accretion of discounts were reclassified for consistency with current period presentation. These reclassifications had no effect on reported operating expenses, loss from operations, or net loss.
Comprehensive Income, Policy [Policy Text Block]	'
	Accumulated Other Comprehensive Income (Loss)
	Comprehensive income or loss is comprised of net income or loss and other comprehensive income or loss. Other comprehensive income or loss includes unrealized gains and losses on the Company’s available-for-sale investments. In addition to unrealized gains and losses on investments, accumulated other comprehensive income or loss consists of foreign currency translation adjustments which arose from the conversion of the Canadian dollar functional currency consolidated financial statements to the U.S. dollar reporting currency consolidated financial statements prior to January 1, 2008. Should the Company liquidate or substantially liquidate its investments in its foreign subsidiaries, the Company would be required to recognize the related cumulative translation adjustments pertaining to the liquidated or substantially liquidated subsidiaries, as a charge to earnings in the Company’s condensed consolidated statement of operations and comprehensive loss.

Note_2_Basis_of_Presentation_T

Note 2 - Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
		Three months ended September 30, 2013
		Net unrealized		Foreign			Accumulated
		gains/(losses) on		Currency			Other
		Available-for-sale		Translation			Comprehensive
		Securities		Adjustment			Loss
		(In thousands)
	Balance at June 30, 2013	$	9	$	(5,066	)	$	(5,057	)
	Current period other comprehensive income		22		—			22
	Balance at September 30, 2013	$	31	$	(5,066	)	$	(5,035	)
		Nine months ended September 30, 2013
		Net unrealized		Foreign			Accumulated
		gains/(losses) on		Currency			Other
		Available-for-sale		Translation			Comprehensive
		Securities		Adjustment			Loss
		(In thousands)
	Balance at December 31, 2012	$	30	$	(5,066	)	$	(5,036	)
	Current period other comprehensive income		1		—			1
	Balance at September 30, 2013	$	31	$	(5,066	)	$	(5,035	)

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
		30-Sep-13								31-Dec-12
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
		(In thousands)
	Financial assets:
	Money market funds	$	10,636	$	—	$	—	$	10,636	$	19,859	$	—	$	—	$	19,859
	Debt securities of U.S. government agencies		—		45,602		—		45,602		—		52,444		—		52,444
	Corporate bonds		—		13,540		—		13,540		—		9,046		—		9,046
		$	10,636	$	59,142	$	—	$	69,778	$	19,859	$	61,490	$	—	$	81,349
	Financial liabilities:
	Restricted share units	$	445	$	—	$	—	$	445	$	271	$	—	$	—	$	271
	Warrants	$	—	$	—	$	2,125	$	2,125	$	—	$	—	$	3,251	$	3,251

Note_5_Financial_Instruments_T

Note 5 - Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Unrealized Gain (Loss) on Investments [Table Text Block]	'
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(In thousands)
	As of September 30, 2013
	Cash	$	2,138	$	—	$	—		$	2,138
	Money market funds		10,636		—		—			10,636
	Debt securities of U.S. government agencies		45,581		21		—			45,602
	Corporate bonds		13,530		10		—			13,540
	Total	$	71,885	$	31	$	—		$	71,916
	As of December 31, 2012
	Cash	$	2,407	$	—	$	—		$	2,407
	Money market funds		19,859		—		—			19,859
	Debt securities of U.S. government agencies		52,415		29		—			52,444
	Corporate bonds		9,045		3		(2	)		9,046
	Total	$	83,726	$	32	$	(2	)	$	83,756
Investments Classified by Contractual Maturity Date [Table Text Block]	'
		As of September 30, 2013				As of December 31, 2012
		Amortized		Fair		Amortized			Fair
		Cost		Value		Cost			Value
		(In thousands)
	Less than one year	$	59,196	$	59,218	$	78,819		$	78,847
	Greater than one year but less than five years		10,551		10,560		2,500			2,502
	Total	$	69,747	$	69,778	$	81,319		$	81,349

Note_6_Net_Loss_Per_Share_Tabl

Note 6 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
		(in thousands, except share and per share amounts)
	Numerator
	Net loss used to compute net loss per share
	Basic	$	(7,710	)	$	(8,625	)	$	(32,396	)	$	(7,669	)
	Adjustments for change in fair value of warrant liability		—			—			—			(14,336	)
	Diluted	$	(7,710	)	$	(8,625	)	$	(32,396	)	$	(22,005	)
	Denominator
	Weighted average shares outstanding used to compute net loss per share:
	Basic		63,886,874			57,186,749			59,962,328			52,564,914
	Dilutive effect of warrants		—			—			—			1,334,362
	Diluted		63,886,874			57,186,749			59,962,328			53,899,276
	Net loss per share—basic	$	(0.12	)	$	(0.15	)	$	(0.54	)	$	(0.15	)
	Net loss per share—diluted	$	(0.12	)	$	(0.15	)	$	(0.54	)	$	(0.41	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Director and employee stock options		2,909,699			2,482,862			2,909,699			2,482,862
	Warrants		10,922,090			5,922,089			10,922,090			48,701
	Non-employee director restricted share units		215,829			140,968			215,829			140,968
	Employee stock purchase plan		23,374			19,223			23,374			19,223

Note_8_Warrants_Tables

Note 8 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2013
Warrants and Rights Note Disclosure [Abstract]	'
Schedule Of Warrants Valuation Assumptions Table Text Block	'
		As of September 30, 2013
		May-09			Sep-10
		Warrants			Warrants
	Exercise price	$	3.74		$	4.24
	Market value of stock at end of period	$	2.06		$	2.06
	Expected dividend rate		0	%		0.00%
	Expected volatility		61.5	%		88.5	%
	Risk-free interest rate		0.1	%		0.3	%
	Expected life (in years)		0.65			2.03
		As of December 31, 2012
		May-09			Sep-10
		Warrants			Warrants
	Exercise price	$	3.74		$	4.24
	Market value of stock at end of period	$	1.92		$	1.92
	Expected dividend rate		0	%		0	%
	Expected volatility		99.2	%		81.1	%
	Risk-free interest rate		0.2	%		0.3	%
	Expected life (in years)		1.4			2.78
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
		Three months ended September 30,
		2013			2012
		(In thousands)
	Balance at beginning of period	$	1,951		$	13,463
	Change in fair value of warrant liability included in:
	Other expense (income)		174			972
	Balance at the end of period	$	2,125		$	14,435
		Nine months ended September 30,
		2013			2012
		(In thousands)
	Balance at beginning of period	$	3,251		$	28,771
	Change in fair value of warrant liability included in:
	Other expense (income)		(1,126	)		(14,336	)
	Balance at the end of period	$	2,125		$	14,435

Note_9_Sharebased_Compensation1

Note 9 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Weighted average grant-date fair value for stock options granted	$	1.27		$	3.62		$	1.27		$	3.63
	Expected dividend rate		0	%		0	%		0	%		0	%
	Expected volatility		89.64	%		84.78	%		89.64	%		84.62	%
	Risk-free interest rate		1.8	%		0.86	%		1.8	%		0.9	%
	Expected life of options in years		6			6			6			6

Note_2_Basis_of_Presentation_D

Note 2 - Basis of Presentation (Details) - Changes in Accumulated Other Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Changes in Accumulated Other Comprehensive Loss [Abstract]	'	'	'	'
Balance of Net unrealized gains/(losses) on Available-for-sale Securities	$9	'	$30	'
Balance of Foreign Currency Translation Adjustment	-5,066	'	-5,066	'
Balance of Accumulated Other Comprehensive Loss	-5,057	'	-5,036	'
Change in Net unrealized gains/(losses) on Available-for-sale Securities	22	'	1	'
Change in Foreign Currency Translation Adjustment	0	'	0	'
Change in Accumulated Other Comprehensive Loss	22	38	1	9
Balance of Net unrealized gains/(losses) on Available-for-sale Securities	31	'	31	'
Balance of Foreign Currency Translation Adjustment	-5,066	'	-5,066	'
Balance of Accumulated Other Comprehensive Loss	($5,035)	'	($5,035)	'

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	$69,778	$81,349
Restricted Share Units [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Liabilities	445	271
Restricted Share Units [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Liabilities	445	271
Warrants [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Liabilities	2,125	3,251
Warrants [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Liabilities	2,125	3,251
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	10,636	19,859
Money Market Funds [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	10,636	19,859
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	45,602	52,444
US Government Agencies Debt Securities [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	45,602	52,444
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	13,540	9,046
Corporate Debt Securities [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	13,540	9,046
Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	10,636	19,859
Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	$59,142	$61,490

Note_5_Financial_Instruments_D

Note 5 - Financial Instruments (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Note 5 - Financial Instruments (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments [Line Items]	'	'
Amortized Cost	$2,138	$2,407
Fair Value	2,138	2,407
Amortized Cost	10,636	19,859
Fair Value	10,636	19,859
Gross Unrealized Gains	31	32
Gross Unrealized Losses	'	-2
Fair Value	69,778	81,349
Cash Cash Equivalents And Available ForSale Debt Securities At Amortized Cost	71,885	83,726
Cash Cash Equivalents And Available For Sale Debt Securities A tFai rValue	71,916	83,756
US Government Agencies Debt Securities [Member]	'	'
Note 5 - Financial Instruments (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments [Line Items]	'	'
Amortized Cost	45,581	52,415
Gross Unrealized Gains	21	29
Fair Value	45,602	52,444
Corporate Debt Securities [Member]	'	'
Note 5 - Financial Instruments (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments [Line Items]	'	'
Amortized Cost	13,530	9,045
Gross Unrealized Gains	10	3
Gross Unrealized Losses	'	-2
Fair Value	$13,540	$9,046

Note_5_Financial_Instruments_D1

Note 5 - Financial Instruments (Details) - Summary of Available-for-Sale Securities by Contractual Maturity (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Summary of Available-for-Sale Securities by Contractual Maturity [Abstract]	'	'
Less than one year	$59,196	$78,819
Less than one year	59,218	78,847
Greater than one year but less than five years	10,551	2,500
Greater than one year but less than five years	10,560	2,502
Total	69,747	81,319
Total	$69,778	$81,349

Note_6_Net_Loss_Per_Share_Deta

Note 6 - Net Loss Per Share (Details) - Reconciliation of the Numerator and Denominator Used in the Caluclation of Basic and Diluted Net Income or Loss Per Share (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator	'	'	'	'
Basic (in Dollars)	($7,710)	($8,625)	($32,396)	($7,669)
Adjustments for change in fair value of warrant liability (in Dollars)	'	'	'	-14,336
Diluted (in Dollars)	($7,710)	($8,625)	($32,396)	($22,005)
Basic	63,886,874	57,186,749	59,962,328	52,564,914
Dilutive effect of warrants	'	'	'	1,334,362
Diluted	63,886,874	57,186,749	59,962,328	53,899,276
Net loss per share—basic (in Dollars per share)	($0.12)	($0.15)	($0.54)	($0.15)
Net loss per share—diluted (in Dollars per share)	($0.12)	($0.15)	($0.54)	($0.41)

Note_6_Net_Loss_Per_Share_Deta1

Note 6 - Net Loss Per Share (Details) - Number of Shares Excluded from the Number of Shares Used to Calculate Diluted Net Income or Loss Per Share	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Director And Employee Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of shares excluded	2,909,699	2,482,862	2,909,699	2,482,862
Warrant [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of shares excluded	10,922,090	5,922,089	10,922,090	48,701
Non-Employee Director Restricted Share Units [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of shares excluded	215,829	140,968	215,829	140,968
Employee Stock Purchase Plan [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of shares excluded	23,374	19,223	23,374	19,223

Note_7_Equity_Based_Transactio1

Note 7 - Equity Based Transactions (Details) (USD $)	0 Months Ended		3 Months Ended				3 Months Ended
	Jun. 04, 2013	Apr. 03, 2012	Sep. 30, 2013	Feb. 03, 2012	Dec. 05, 2018	Jun. 30, 2013	Sep. 30, 2013
					June 2013 Warrants [Member]	June 2013 Warrants [Member]	Common Stock [Member]
Note 7 - Equity Based Transactions (Details) [Line Items]	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	5,000,000	13,512,500	'	'	'	'	5,791,697
Sale Price of Common Stock And Warrants Per Unit (in Dollars per Item)	2	'	'	'	'	'	'
Proceeds From Issuance of Common Stock Gross	$10,000,000	$54,100,000	$11,500,000	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	'	'	'	'	5	5	'
Proceeds from Issuance or Sale of Equity	9,900,000	50,300,000	11,200,000	'	'	'	'
Sale of Stock, Price Per Share (in Dollars per share)	'	$4	'	'	'	'	'
Aggregate Gross Sales Proceeds Under Sales Agreement	'	'	'	50,000,000	'	'	'
Sales Agreement Compensation Percentage	'	'	'	3.00%	'	'	'
Payments of Stock Issuance Costs	'	'	300,000	'	'	'	'
Offering Proceeds Receivable	'	'	1,400,000	'	'	'	'
Remaining Gross Sales Proceeds Under Sales Agreement	'	'	$38,500,000	'	'	'	'

Note_8_Warrants_Details

Note 8 - Warrants (Details) (USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 05, 2018	Jun. 30, 2013	Feb. 08, 2011	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013
		June 2013 Warrants [Member]	June 2013 Warrants [Member]	February 2011 Warrants [Member]	Warrants Classified as Equity [Member]	May 2009 Warrants [Member]	May 2009 Warrants [Member]	September 2010 Warrants [Member]	September 2010 Warrants [Member]	Warrants Classified as Liability [Member]
Note 8 - Warrants (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Class of Warrant or Right, Outstanding	10,922,090	'	'	'	'	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	5,000,000	48,701	5,048,701	2,691,242	'	3,182,147	'	5,873,389
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	'	5	5	3.08	'	3.74	3.74	4.24	4.24	'
Fair Value Measurements Sensitivity Analysis Amount (in Dollars)	$0.40	'	'	'	'	'	'	'	'	'

Note_8_Warrants_Details_Estima

Note 8 - Warrants (Details) - Estimated Fair Value of Outstanding Warrants (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
May 2009 Warrants [Member]	'	'
Note 8 - Warrants (Details) - Estimated Fair Value of Outstanding Warrants [Line Items]	'	'
Exercise price (in Dollars per Item)	3.74	3.74
Market value of stock at end of period (in Dollars per share)	$2.06	$1.92
Expected dividend rate	0.00%	0.00%
Expected volatility	61.50%	99.20%
Risk-free interest rate	0.10%	0.20%
Expected life (in years)	'237 days	'1 year 146 days
September 2010 Warrants [Member]	'	'
Note 8 - Warrants (Details) - Estimated Fair Value of Outstanding Warrants [Line Items]	'	'
Exercise price (in Dollars per Item)	4.24	4.24
Market value of stock at end of period (in Dollars per share)	$2.06	$1.92
Expected dividend rate	0.00%	0.00%
Expected volatility	88.50%	81.10%
Risk-free interest rate	0.30%	0.30%
Expected life (in years)	'2 years 10 days	'2 years 284 days

Note_8_Warrants_Details_Change

Note 8 - Warrants (Details) - Change in Fair Value of the Warrant Liability (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Change in Fair Value of the Warrant Liability [Abstract]	'	'	'	'
Balance at beginning of period	$1,951	$13,463	$3,251	$28,771
Other expense (income)	174	972	-1,126	-14,336
Balance at the end of period	$2,125	$14,435	$2,125	$14,435

Note_9_Sharebased_Compensation2

Note 9 - Share-based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Jun. 03, 2010
Note 9 - Share-based Compensation (Details) [Line Items]	'	'	'	'	'
Maximum Fixed Reloading Percentage	'	'	10.00%	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	10,000	75,000	10,000	100,500	'
Share Reserved Employee Stock Purchase Plan Share	'	'	'	'	900,000
Employee Stock Purchase Plan Maximum Payroll Deduction Percentage	'	'	15.00%	'	'
Employee Stock Purchase Plan Maximum Value Of Compensation Per Employee (in Dollars)	'	'	$25,000	'	'
Employee Stock Purchase Plan Purchase Of Common Stock Percentage	'	'	85.00%	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee	'	'	15,000	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	'	'	35,895	28,591	'
Restricted Share Units Maximum Shares Reserved	466,666	'	466,666	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	17,341	'	97,551	40,870	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$30,000	'	$180,000	$150,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	22,690	43,397	'
Value Shares Withheld Restricted Share Unit Percentage	'	'	25.00%	'	'
Stock Option Plan [Member]	'	'	'	'	'
Note 9 - Share-based Compensation (Details) [Line Items]	'	'	'	'	'
Common Stock, Capital Shares Reserved for Future Issuance	6,806,084	'	6,806,084	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,794,003	'	2,794,003	'	'
Allocated Share-based Compensation Expense (in Dollars)	400,000	300,000	1,300,000	1,000,000	'
Employee Stock Purchase Plan [Member]	'	'	'	'	'
Note 9 - Share-based Compensation (Details) [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	716,278	'	716,278	'	'
Allocated Share-based Compensation Expense (in Dollars)	44,273	54,928	107,847	134,030	'
Restricted Share Unit Plan [Member]	'	'	'	'	'
Note 9 - Share-based Compensation (Details) [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	79,022	'	79,022	'	'
Allocated Share-based Compensation Expense (in Dollars)	$100,000	100,000	$200,000	($200,000)	'

Note_9_Sharebased_Compensation3

Note 9 - Share-based Compensation (Details) - Weighted Average Assumptions (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Weighted Average Assumptions [Abstract]	'	'	'	'
Weighted average grant-date fair value for stock options granted (in Dollars per share)	$1.27	$3.62	$1.27	$3.63
Expected dividend rate	0.00%	0.00%	0.00%	0.00%
Expected volatility	89.64%	84.78%	89.64%	84.62%
Risk-free interest rate	1.80%	0.86%	1.80%	0.90%
Expected life of options in years	'6	'6	'6	'6

Note_10_Contingencies_Commitme1

Note 10 - Contingencies, Commitments, and Guarantees (Details)	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Royalty Payment Percentage	3.00%

Note_11_Collaborative_and_Lice1

Note 11 - Collaborative and License Agreements (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Note 11 - Collaborative and License Agreements (Details) [Line Items]	'	'	'	'
Research and Development Expense	$5,517,000	$5,783,000	$27,374,000	$16,348,000
Upfront Payment [Member]	'	'	'	'
Note 11 - Collaborative and License Agreements (Details) [Line Items]	'	'	'	'
Research and Development Expense	'	'	10,000,000	'
Milestone Payments [Member]	'	'	'	'
Note 11 - Collaborative and License Agreements (Details) [Line Items]	'	'	'	'
Contingent Receipts Under License Agreement	'	'	$90,000,000	'